Letter by Krijnen et al Regarding Article, “The sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Percutaneous coronary intervention (PCI) may induce a variable amount of myocardial necrosis. It is now well accepted that increased blood levels of the plasma inflammatory marker secretory phospholipase A2 (sPLA2) correlate with cardiac injury in patients undergoing PCI,1 and a role for sPLA2 in PCI-related cardiac injury has been hypothesized. Using the sPLA2 inhibitor varespladib, Dzavik et al2 tested this hypothesis in the sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial. However, their results did not support a cardioprotective effect of …